|
|
||||||||||
|
J Am Coll Cardiol, 2003; 41:1283-1288, doi:10.1016/S0735-1097(03)00119-0 © 2003 by the American College of Cardiology Foundation |






* Deutsches Herzzentrum, Munich, Germany
1. Medizinische Klinik rechts der Isar, Munich, Germany
Medizinische Klinik I, Garmisch-Partenkirchen, Germany
Medizinische Klinik I, Ingolstadt, Germany
Manuscript received April 23, 2002; revised manuscript received June 17, 2002, accepted June 26, 2002.
* Reprint requests and correspondence: Dr. Adnan Kastrati, Deutsches Herzzentrum, Lazarettstr. 36, 80636 München, Germany.
kastrati{at}dhm.mhn.de
OBJECTIVES: We tested the hypothesis that thinner-strut stents are associated with a reduced rate of restenosis when comparing two stents with different design.
BACKGROUND: We have previously shown that, for two stents with similar design, the risk for restenosis is dependent on the strut thickness. It is unknown whether strut thickness preserves its relevance as a determinant of restenosis even in the presence of different stent designs.
METHODS: A total of 611 patients with symptomatic coronary artery disease were randomly assigned to receive either the thin-strut ACS RX Multilink stent (Guidant, Advanced Cardiovascular Systems, Santa Clara, California) (strut thickness 50 µm, interconnected ring design; n = 309) or the thick-strut BX Velocity stent (Cordis Corp., Miami, Florida) (strut thickness 140 µm, closed cell design; n = 302). The primary end point was angiographic restenosis (
50% diameter stenosis at follow-up angiography). Secondary end points were the incidence of target-vessel revascularization (TVR) and the combined rate of death and myocardial infarction (MI) at one year.
RESULTS: The incidence of angiographic restenosis was 17.9% in the thin-strut group and 31.4% in the thick-strut group, relative risk, 0.57 (95% confidence interval, 0.39 to 0.84), p < 0.001. A TVR due to restenosis was required in 12.3% of the thin-strut group and 21.9% of the thick-strut group, relative risk, 0.56 (95% confidence interval, 0.38 to 0.84), p = 0.002. No significant difference was observed in the combined incidence of death and MI at one year.
CONCLUSIONS: When two stents with different design are compared, the stent with thinner struts elicits less angiographic and clinical restenosis than the thicker-strut stent.
| ||||||||||||||
This article has been cited by other articles:
![]() |
B. Chevalier, C. Di Mario, F.-J. Neumann, F. Ribichini, P. Urban, J. J. Popma, P. J. Fitzgerald, D. E. Cutlip, D. O. Williams, J. Ormiston, et al. A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 524 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F. D. Kolodgie, H. K. Gold, et al. Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 535 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija, Q. Cheng, X. Xu, et al. Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents J. Am. Coll. Cardiol., July 29, 2008; 52(5): 333 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Vlaar, B. J. G. L. de Smet, and F. Zijlstra DES or BMS in acute myocardial infarction? Eur. Heart J., November 2, 2007; 28(22): 2693 - 2694. [Full Text] [PDF] |
||||
![]() |
C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience Angiology, November 1, 2007; 58(5): 523 - 534. [Abstract] [PDF] |
||||
![]() |
M. Menichelli, A. Parma, E. Pucci, R. Fiorilli, F. De Felice, M. Nazzaro, A. Giulivi, D. Alborino, A. Azzellino, and R. Violini Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI) J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1924 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tung, S. Kaul, G. A. Diamond, and P. K. Shah Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med, June 20, 2006; 144(12): 913 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials Heart, May 1, 2006; 92(5): 650 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
Additional Information JAMA, March 15, 2006; 295(11): E1 - E6. [Full Text] [PDF] |
||||
![]() |
U Dietz, N Holz, C Dauer, and H Lambertz Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting Heart, January 1, 2006; 92(1): 80 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Holzapfel, G. Sommer, C. T. Gasser, and P. Regitnig Determination of layer-specific mechanical properties of human coronary arteries with nonatherosclerotic intimal thickening and related constitutive modeling Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2048 - H2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Monraats, N. M.M. Pires, W. R.P. Agema, A. H. Zwinderman, A. Schepers, M. P.M. de Maat, P. A. Doevendans, R. J. de Winter, R. A. Tio, J. Waltenberger, et al. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions Circulation, October 18, 2005; 112(16): 2417 - 2425. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Butany, K Carmichael, S W Leong, and M J Collins Coronary artery stents: identification and evaluation J. Clin. Pathol., August 1, 2005; 58(8): 795 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Serruys, G. Sianos, A. Abizaid, J. Aoki, P. den Heijer, H. Bonnier, P. Smits, D. McClean, S. Verheye, J. Belardi, et al. The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform: The Paclitaxel In-Stent Controlled Elution Study (PISCES) J. Am. Coll. Cardiol., July 19, 2005; 46(2): 253 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pache, A. Dibra, J. Mehilli, J. Dirschinger, A. Schomig, and A. Kastrati Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial Eur. Heart J., July 1, 2005; 26(13): 1262 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Windecker, R. Simon, M. Lins, V. Klauss, F. R. Eberli, M. Roffi, G. Pedrazzini, T. Moccetti, P. Wenaweser, M. Togni, et al. Randomized Comparison of a Titanium-Nitride-Oxide-Coated Stent With a Stainless Steel Stent for Coronary Revascularization: The TiNOX Trial Circulation, May 24, 2005; 111(20): 2617 - 2622. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rana, P. S. Monraats, A. H. Zwinderman, M. P.M. de Maat, J. J.P. Kastelein, P. A.F. Doevendans, R. J. de Winter, R. A. Tio, R. R. Frants, A. van der Laarse, et al. Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention Diabetes Care, April 1, 2005; 28(4): 873 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Finn, I. F. Palacios, A. Kastrati, and H. K. Gold Drug-eluting stents for diabetes mellitus: A rush to judgment? J. Am. Coll. Cardiol., February 15, 2005; 45(4): 479 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R.P Agema, P. S Monraats, A. H Zwinderman, R. J de Winter, R. A Tio, P. A.F.M Doevendans, J. Waltenberger, M. P.M de Maat, R. R Frants, D. E Atsma, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era Eur. Heart J., July 1, 2004; 25(13): 1163 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Moreno, C. Fernandez, F. Alfonso, R. Hernandez, M. J. Perez-Vizcayno, J. Escaned, M. Sabate, C. Banuelos, D. J. Angiolillo, L. Azcona, et al. Coronary stenting versus balloon angioplasty in small vessels: A meta-analysis from 11 randomized studies J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1964 - 1972. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kereiakes, A. M. Szyniszewski, D. Wahr, H. C. Herrmann, D. I. Simon, C. Rogers, P. Kramer, W. Shear, A. C. Yeung, K. A. Shunk, et al. Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment: Procedural and Long-Term Results Circulation, September 16, 2003; 108(11): 1310 - 1315. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Berger Can euphoria be bad? J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1289 - 1292. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |